{"id":19135,"date":"2020-06-15T14:23:30","date_gmt":"2020-06-15T12:23:30","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=19135"},"modified":"2022-06-30T15:21:50","modified_gmt":"2022-06-30T13:21:50","slug":"rentabilidad-de-tratamiento-para-leucemia-mieloide-aguda","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/rentabilidad-de-tratamiento-para-leucemia-mieloide-aguda\/","title":{"rendered":"Rentabilidad de tratamiento para leucemia mieloide aguda"},"content":{"rendered":"<p>El uso de gemtuzumab ozogamicina en combinaci\u00f3n con quimioterapia est\u00e1ndar (idarubicina y citarabina) como 1\u00aa l\u00ednea de tratamiento en pacientes con leucemia mieloide aguda de novo en Espa\u00f1a, es una opci\u00f3n de tratamiento coste-efectiva frente a quimioterapia est\u00e1ndar para el sistema sanitario. Estas conclusiones proceden de los datos recogidos en la Comunicaci\u00f3n:\u00a0<em>Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy for first-line treatment of patients with CD33-positive acute myeloid leukemia in Spain<\/em>, que PORIB ha presentado en el\u00a0<em>25th European Hematology Association Congress<\/em>, celebrado en modalidad virtual del 11 al 14 de junio de 2020.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El uso de gemtuzumab ozogamicina en combinaci\u00f3n con quimioterapia est\u00e1ndar (idarubicina y citarabina) como 1\u00aa l\u00ednea de tratamiento en pacientes con leucemia mieloide aguda de novo en Espa\u00f1a, es una opci\u00f3n de tratamiento coste-efectiva frente a quimioterapia est\u00e1ndar para el sistema sanitario. Estas conclusiones proceden de los datos recogidos en la Comunicaci\u00f3n:\u00a0Cost-effectiveness of gemtuzumab ozogamicin&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/porib.com\/en\/rentabilidad-de-tratamiento-para-leucemia-mieloide-aguda\/\" class=\"excerpt-read-more\">Read More<i class=\"fa fa-caret-right icon-caret-right\"><\/i><\/a><\/p>\n","protected":false},"author":4,"featured_media":19136,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[67],"tags":[],"class_list":["post-19135","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ultimas-noticias"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/19135"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=19135"}],"version-history":[{"count":1,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/19135\/revisions"}],"predecessor-version":[{"id":19137,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/19135\/revisions\/19137"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media\/19136"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=19135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=19135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=19135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}